Key result
Low serum TTR tetramer is linked to ~2.2-fold higher all-cause mortality in heart failure.
Why the study?
Low plasma transthyretin tetramer levels have been associated with heart failure risk in the general population, but their prognostic value in patients with heart failure is unknown.
Are low circulating serum transthyretin (TTR) tetramer levels associated with increased all-cause mortality and rehospitalization in patients with acute decompensated heart failure?
Cohort (n=2,178)
No
Are low circulating serum transthyretin (TTR) tetramer levels associated with increased all-cause mortality and rehospitalization in patients with acute decompensated heart failure?
Answers are grounded in this paper and cite their sources.
Serum transthyretin tetramer is an independent prognostic biomarker for all-cause mortality and rehospitalization in heart failure that provides incremental risk stratification value over NT-proBNP.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) conducted a cohort in Acute decompensated heart failure (NYHA class II-IV) (n=2,178). Low serum transthyretin (TTR) tetramer levels (<2.75 μmol/L, lowest tertile) vs. Moderate or high serum TTR tetramer levels (≥2.75 μmol/L) and healthy controls was evaluated on All-cause mortality (HR 2.19, 95% CI 1.05-4.55, p=0.036). Low serum TTR tetramer was independently associated with higher all-cause mortality in patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: